PHARMACEUTICAL 2015

XOMA Royalty Corp
Rank 220 of 274



PHARMACEUTICAL 2015

XOMA Royalty Corp
Rank 220 of 274

The relative strengths and weaknesses of XOMA Royalty Corp are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of XOMA Royalty Corp compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 8.1% points.The greatest weakness of XOMA Royalty Corp is the variable Stockholders Equity, reducing the Economic Capital Ratio by 156% points.

The company's Economic Capital Ratio, given in the ranking table, is 140%, being 114% points below the market average of 254%.

Input Variable	Value in 1000 USD
Assets, Current	83,842
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	36,475
Liabilities, Non-Current	16,290
Other Assets	669
Other Compr. Net Income	0
Other Expenses	4,387
Other Liabilities	33,767
Other Net Income	47,834
Other Revenues	18,866
Property and Equipment	5,120
Research and Development	80,748
Selling, General and Administrative Expense	19,866

Output Variable	Value in 1000 USD
Assets	89,631
Liabilities	86,532
Expenses	105,001
Revenues	18,866
Stockholders Equity	3,099
Net Income	-38,301
Comprehensive Net Income	-38,301
BaseVar	173,932
ECR before LimitedLiability	-36%
Economic Capital Ratio	140%